X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (39) 39
beer (29) 29
biochemistry (29) 29
chemistry (29) 29
compositions or test papers therefor (29) 29
condition-responsive control in microbiological orenzymological processes (29) 29
enzymology (29) 29
measuring or testing processes involving enzymes, nucleicacids or microorganisms (29) 29
metallurgy (29) 29
microbiology (29) 29
mutation or genetic engineering (29) 29
organic chemistry (29) 29
processes of preparing such compositions (29) 29
spirits (29) 29
vinegar (29) 29
wine (29) 29
oncology (28) 28
female (26) 26
male (26) 26
middle aged (26) 26
aged (23) 23
adult (21) 21
aged, 80 and over (17) 17
colorectal neoplasms - drug therapy (17) 17
antineoplastic combined chemotherapy protocols - therapeutic use (15) 15
compositions thereof (15) 15
culture media (15) 15
derivatives thereof (15) 15
heterocyclic compounds (15) 15
human necessities (15) 15
hygiene (15) 15
index medicus (15) 15
medical or veterinary science (15) 15
microorganisms or enzymes (15) 15
nucleic acids (15) 15
nucleosides (15) 15
nucleotides (15) 15
preparations for medical, dental, or toilet purposes (15) 15
propagating, preserving or maintaining microorganisms (15) 15
specific therapeutic activity of chemical compounds ormedicinal preparations (15) 15
sugars (15) 15
chemotherapy (13) 13
colorectal neoplasms - genetics (13) 13
colorectal cancer (11) 11
treatment outcome (11) 11
fluorouracil - administration & dosage (10) 10
polymorphism, genetic (10) 10
cancer (9) 9
survival rate (9) 9
fermentation or enzyme-using processes to synthesise a desiredchemical compound or composition or to separate optical isomersfrom a racemic mixture (8) 8
fluorouracil - therapeutic use (8) 8
leucovorin (8) 8
organoplatinum compounds - administration & dosage (8) 8
oxaliplatin (8) 8
retrospective studies (8) 8
antineoplastic agents - therapeutic use (7) 7
colorectal neoplasms - pathology (7) 7
fluorouracil (7) 7
genotype (7) 7
hematology, oncology and palliative medicine (7) 7
leucovorin - administration & dosage (7) 7
messenger-rna levels (7) 7
peptides (7) 7
polymorphism (7) 7
polymorphism, restriction fragment length (7) 7
prognosis (7) 7
thymidylate synthase - genetics (7) 7
tumors (7) 7
antineoplastic combined chemotherapy protocols - adverse effects (6) 6
cisplatin (6) 6
colorectal neoplasms - enzymology (6) 6
expression (6) 6
gene expression regulation, neoplastic (6) 6
pharmacogenetics (6) 6
single nucleotide polymorphism (6) 6
survival (6) 6
survival analysis (6) 6
adenocarcinoma - drug therapy (5) 5
animals (5) 5
antineoplastic combined chemotherapy protocols - administration & dosage (5) 5
biomarkers, tumor - genetics (5) 5
cancer therapies (5) 5
cisplatin - administration & dosage (5) 5
colorectal neoplasms - mortality (5) 5
dna primers (5) 5
follow-up studies (5) 5
organoplatinum compounds - therapeutic use (5) 5
polymerase chain reaction (5) 5
risk factors (5) 5
stomach neoplasms - drug therapy (5) 5
thymidylate-synthase gene (5) 5
5-fluorouracil (4) 4
base sequence (4) 4
cancer patients (4) 4
care and treatment (4) 4
cetuximab (4) 4
colorectal-cancer (4) 4
disease-free survival (4) 4
dna repair (4) 4
dna-binding proteins (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 1, pp. 38 - 47
Summary Background Neoadjuvant chemotherapy for unresectable colorectal liver metastases can downsize tumours for curative resection. We assessed the... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | 1ST-LINE TREATMENT | LEUCOVORIN | PLUS IRINOTECAN | ONCOLOGY | BEVACIZUMAB | OXALIPLATIN | FLUOROURACIL | HEPATIC RESECTION | CANCER | CARCINOMA | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Antineoplastic Agents - therapeutic use | Tomography, Spiral Computed | Liver Neoplasms - chemistry | Hepatectomy | Antibodies, Monoclonal, Humanized | Fluorouracil - therapeutic use | Austria | Leucovorin - adverse effects | Fluorouracil - adverse effects | Time Factors | Antineoplastic Agents - adverse effects | Female | Leucovorin - therapeutic use | Neoadjuvant Therapy | Retrospective Studies | Chemotherapy, Adjuvant | Cetuximab | Liver Neoplasms - secondary | Odds Ratio | Camptothecin - analogs & derivatives | Camptothecin - adverse effects | Camptothecin - therapeutic use | Liver Neoplasms - genetics | Risk Assessment | Liver Neoplasms - drug therapy | Linear Models | Liver Neoplasms - surgery | Proto-Oncogene Proteins - genetics | Treatment Outcome | Receptor, Epidermal Growth Factor - analysis | Magnetic Resonance Imaging | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Aged | Mutation | Colorectal Neoplasms - pathology | Organoplatinum Compounds - therapeutic use | Germany | Organoplatinum Compounds - adverse effects | Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 13, pp. 1355 - 1369
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2008, Volume 26, Issue 9, pp. 1435 - 1442
Journal Article
The Lancet, ISSN 0140-6736, 05/2019, Volume 393, Issue 10184, pp. 1948 - 1957
Docetaxel-based chemotherapy is effective in metastatic gastric and gastro-oesophageal junction adenocarcinoma. This study reports on the safety and efficacy... 
SURGERY | REGRESSION | MEDICINE, GENERAL & INTERNAL | MULTICENTER | RESECTION | CHEMORADIOTHERAPY | OPEN-LABEL | ESOPHAGEAL | CANCER | STOMACH | Capecitabine - administration & dosage | Leucovorin - administration & dosage | Adenocarcinoma - pathology | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Male | Oxaliplatin - therapeutic use | Stomach Neoplasms - pathology | Cisplatin - administration & dosage | Fluorouracil - therapeutic use | Docetaxel - administration & dosage | Fluorouracil - administration & dosage | Aged, 80 and over | Adult | Female | Leucovorin - therapeutic use | Oxaliplatin - administration & dosage | Administration, Oral | Esophagogastric Junction - pathology | Treatment Outcome | Capecitabine - therapeutic use | Stomach Neoplasms - drug therapy | Adenocarcinoma - drug therapy | Disease-Free Survival | Digestive System Surgical Procedures | Cisplatin - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Docetaxel - therapeutic use | Aged | Neoplasm Staging | Adenocarcinoma | Anthracyclines | Chemotherapy | Leucovorin | Product development | Esophageal cancer | Cancer | Intravenous administration | Control methods | Toxicity | Clinical trials | Oncology | Metastasis | Cancer therapies | Stomach cancer | Metastases | Confidence intervals | Infusion | Oxaliplatin | Motivation | Surgery | Intravenous infusion | Epirubicin | Medical research | Survival | Patients | Cisplatin | Esophagus | Interactive systems | Medical prognosis | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
PLoS ONE, ISSN 1932-6203, 05/2013, Volume 8, Issue 5, p. e64186
Background: Cholangiocarcinoma remains to be a tumor with very few treatment choices and limited prognosis. In this study, we sought to determine the... 
LUNG-CANCER | CELLS | VEGF | MULTIDISCIPLINARY SCIENCES | PDGFA | HIGH EXPRESSION | BFGF | PANCREATIC DUCTAL ADENOCARCINOMAS | HIF1A | CHEMOTHERAPY | Receptor, Epidermal Growth Factor - genetics | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Glucuronidase - metabolism | Male | Bile Duct Neoplasms - enzymology | Receptor, Epidermal Growth Factor - metabolism | Statistics, Nonparametric | Aged, 80 and over | Biomarkers, Tumor - metabolism | Female | Bile Duct Neoplasms - genetics | Cholangiocarcinoma - enzymology | Vascular Endothelial Growth Factor Receptor-1 - genetics | Bile Ducts, Intrahepatic - pathology | Risk Factors | Kaplan-Meier Estimate | Vascular Endothelial Growth Factor Receptor-1 - metabolism | Bile Ducts, Intrahepatic - enzymology | Cholangiocarcinoma - pathology | Glucuronidase - genetics | Survival Analysis | Cholangiocarcinoma - genetics | ROC Curve | Aged | Biomarkers, Tumor - genetics | Bile Duct Neoplasms - pathology | Tyrosine | Messenger RNA | Genes | Muscle proteins | Gene expression | Growth factors | Formaldehyde | Platelet-derived growth factor | Lung cancer | Oncology | Risk | Metastasis | Paraffin | Kinases | Tissues | Medical diagnosis | Cancer therapies | Subgroups | Epidermal growth factor | Actin | Vascular endothelial growth factor | Protein-tyrosine kinase | Cholangiocarcinoma | Medical research | Lymphatic system | Polypeptides | Internal medicine | Epidermal growth factor receptors | Markers | Regression analysis | Patients | Survival | Polymerase chain reaction | Medicine | Chemotherapy | Hospitals | Hypoxia
Journal Article
Journal Article
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer, ISSN 0080-0015, 2007, Volume 176, pp. 81 - 88
Treatment of gastrointestinal cancers has significantly advanced over the last several years with the introduction of effective chemotherapeutic and targeted... 
Antineoplastic Agents - metabolism | Prognosis | Antineoplastic Agents - adverse effects | Colorectal Neoplasms - drug therapy | Enzymes - genetics | Humans | Treatment Outcome | Polymorphism, Genetic
Journal Article
Annals of the New York Academy of Sciences, ISSN 0077-8923, 08/2008, Volume 1137, Issue 1, pp. 190 - 196
Journal Article
Journal Article
Journal Article